Market Overview

Opko Health And Teva Pharmaceutical Industries Surge Following Director's Resignation

Related OPK
Lightning Round: Jim Cramer Gives His Opinion On Lowe's Companies, Blackstone And More
51 Biggest Movers From Yesterday
Related TEVA
Credit Suisse Upgrades Teva After Job Cuts Announced
Goldman Sachs: Now Is The Time To Get In On Teva's Turnaround
Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold (Seeking Alpha)

Shares of Opko Health Inc. (NYSE: OPK) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) surged following the resignation of Teva’s director, as well as an earnings beat.

Dr. Phillip Frost resigned from the Teva Pharmaceutical Industries Board of Directors, effective February 4, 2015. Professor Yitzhak Peterburg assumed the role of Chairman on January 1, a position previously held by Frost.

In a press release, Professor Yitzhak Peterburg said that “Dr. Frost has made significant contributions to Teva since joining the Board in 2006 with Teva’s acquisition of Ivax. He has been deeply influential in Teva’s growth and we have benefitted greatly from his experience and knowledge. We wish him continued success in his distinguished career.”

Dr. Frost currently holds the position of chairman and CEO at Opko Health.

Opko Health recently traded at $13.17, up 3.13 percent.

Teva Pharmaceutical recently traded at $57.96, up 2.6 percent.

Posted-In: Dr. Phillip FrostNews Management Intraday Update


Related Articles (OPK + TEVA)

View Comments and Join the Discussion!